Insights - Medtronic announced better than expected Q1 fiscal year 2024 results yesterday. The diabetes segment of the business generated quarterly sales of $578M, more than 6% … Continue Reading
Read NowInsights - The first seismic shift in diabetes care played out during the last six years when continuous glucose monitoring (CGM) became a norm for diabetes patients … Continue Reading
Read NowInsights - Last week, Gossamer (GOSS) hosted a KOL call to discuss their Phase 2 results, OLE data and upcoming Phase 3 design. Below are notes from … Continue Reading
Read NowInsights - Gossamer (GOSS) released their open label extension (OLE) data this morning. The data release was also accompanied by a $212M private placement. The data, albeit … Continue Reading
Read NowInsights - Radiopharmaceutical companies are primed for increased investor interest as the sector is seeing meaningful progress that is currently being overlooked in favor of ADCs. Tailwinds … Continue Reading
Read NowInsights - Obesity data from big pharma competitors was presented at the American Diabetes Association conference this past weekend. The trend is moving towards developing oral GLP-1 … Continue Reading
Read NowInsights - Day One (DAWN) announced a $150M raise priced at $13/share after presenting additional data at ASCO 2023. Importantly, the company formed a regulatory pathway in … Continue Reading
Premium: Read Now
